Dec 20, 2015

Merck's KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1 | Benzinga

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010...

Proceed to the page:

Similar Articles Added Earlier

Similar Articles Added Today

Latest Links Processed